Low-Dose Rivaroxaban as Extended Prophylaxis Reduces Postdischarge Venous Thromboembolism in Patients With Malignancy...

Area of Science:

• Pharmacology and Therapeutics
• Gastroenterology and Oncology
• Vascular Surgery

Background:

• Guidelines recommend extended prophylaxis for venous thromboembolism (VTE) in colorectal cancer (CRC) and inflammatory bowel disease (IBD) patients, but routine use of oral therapies is low.
• Limited data exist on the efficacy and safety of oral extended prophylaxis for VTE prevention in these high-risk patient populations post-surgery.

Discussion:

• Propensity matching compared VTE incidence before and after implementing extended prophylaxis with low-dose rivaroxaban in CRC and IBD patients undergoing resection.
• The study assessed VTE rates and bleeding complications (major/minor) within 30 days post-discharge.
• Findings suggest that extended prophylaxis with oral rivaroxaban is a viable strategy for reducing VTE in this cohort.

Key Insights:

• Extended prophylaxis using 10mg rivaroxaban for 30 days significantly decreased post-discharge VTE incidence from 4.8% to 0.6% (p=0.019) in CRC and IBD patients.
• The prospective cohort receiving rivaroxaban had a low rate of major bleeding (1.1%), indicating a favorable safety profile.
• This oral regimen offers an effective alternative to traditional extended prophylaxis, addressing current gaps in therapy.

Outlook:

• Future research should involve multi-institutional studies with placebo arms to further validate these findings.
• Investigating long-term outcomes and cost-effectiveness of oral extended prophylaxis is warranted.
• Wider adoption of evidence-based extended prophylaxis protocols can improve patient outcomes and reduce VTE-related morbidity.